RAB22A and combined hepatocellular carcinoma and cholangiocarcinoma: Although RAB22A has recently been reported to be upregulated in hepatocellular carcinoma, cholangiohepatoma [62], melanoma [63] and colorectal cancer [29], little is known about its role in human tumorigenesis, especially in human glioma.